Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

661 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study.
Di Maio M, Bighin C, Schettini F, Ruelle T, Marandino L, Fabi A, De Angelis C, Giuliano M, De Placido P, De Laurentiis M, Riccardi F, Picotto C, Puglisi F, Del Mastro L, Arpino G; Gruppo Italiano Mammella (GIM) Study Group. Di Maio M, et al. Breast. 2023 Dec;72:103583. doi: 10.1016/j.breast.2023.103583. Epub 2023 Sep 25. Breast. 2023. PMID: 37783133 Free PMC article.
Re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007.
Gandaglia G, Briganti A, Raggi D, Marandino L, Necchi A, Di Maio M, Montorsi F. Gandaglia G, et al. Among authors: di maio m. Eur Urol Focus. 2024 May;10(3):497. doi: 10.1016/j.euf.2023.01.024. Epub 2023 Feb 20. Eur Urol Focus. 2024. PMID: 36813620 No abstract available.
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, Esposito L, Famiglietti V, Di Liello A, Avallone A, Cardone C, De Stefano A, Montesarchio V, Zampino MG, Fazio N, Di Maio M, Del Tufo S, De Vita F, Altucci L, Marrone F, Ciardiello F, Troiani T. Napolitano S, et al. Among authors: di maio m, di liello a. Int J Cancer. 2023 Oct 15;153(8):1520-1528. doi: 10.1002/ijc.34632. Epub 2023 Jun 30. Int J Cancer. 2023. PMID: 37391938 Clinical Trial.
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M, Di Maio M, Remon J, Bironzo P, Genova C, Facchinetti F, Aldea M, Le Péchoux C, Novello S, Barlesi F, Besse B, Planchard D. Tagliamento M, et al. Among authors: di maio m. J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9. J Thorac Oncol. 2024. PMID: 37567387 Free article.
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, Ermacora P, Catino A, Pipitone S, Di Napoli M, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Schinzari G, Casadei C, Grossi F, Rizzo M, Montesarchio V, Verderame F, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Tondini CA, Camerini A, Banzi MC, Sorarù M, Zucali PA, Vignani F, Ricciardi S, Russo A, Cosenza A, Di Maio M, De Giorgi U, Pignata S, Giannarelli D, Pinto C, Buti S, Fornarini G, Rebuzzi SE, Rescigno P, Addeo A, Banna GL, Bersanelli M. Anpalakhan S, et al. Among authors: di maio m, di napoli m. iScience. 2023 Sep 22;26(11):107970. doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17. iScience. 2023. PMID: 37860695 Free PMC article.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: di maio m. Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023. Front Oncol. 2024. PMID: 38318323 Free PMC article.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S, Oza A, Hall G, Pardo B, Madry R, Cibula D, Klat J, Montes A, Glasspool R, Colombo N, Pete I, Herrero Ibáñez A, Marín MR, Ilieva R, Timcheva C, Di Maio M, Blakeley C, Taylor R, Barnicle A, Clamp A. Pignata S, et al. Among authors: di maio m. Gynecol Oncol. 2023 May;172:121-129. doi: 10.1016/j.ygyno.2023.03.019. Epub 2023 Apr 6. Gynecol Oncol. 2023. PMID: 37030280 Free article.
661 results